Industry News

• Anika Therapeutics reports 18% revenue drowth in fourth-quarter 2009  Anika Therapeutics reported product revenue increased by 20% to $9,944,000 for the fourth quarter of 2009, compared with $8,285,000 in the same period last year, and net income for the fourth quarter of 2009 was $697,000 versus $1.0 million for the fourth quarter of 2008.
  Anika Therapeutics, Inc. March 16, 2010  
• Star Scientific regains compliance with NASDAQ  Star Scientific reported that after the close of trading on March 16 it received a letter from NASDAQ indicating that Star now has regained compliance with the NASDAQ minimum bid-price listing requirement.
  Star Scientific, Inc. March 16, 2010  
• The Medicines Company announces decision in PTO and FDA litigation  The Medicines Company announced that the District Court for the Eastern District of Virginia set aside the PTO's denial of the Company's patent term extension application and sent the matter back to the PTO for reconsideration.
  The Medicines Company March 16, 2010  
• Molecular Insight reports fourth quarter and year-end 2009 financial results  Molecular Insight resported a net loss of $13.2 million for the quarter ended December 31, 2009 versus a net loss of $15.8 million or $0.63 per share for the fourth quarter of 2008. At December 31, 2009, the Company had approximately $64.0 million in cash, and cash equivalents.
  Molecular Insight Pharmaceuticals, Inc. March 16, 2010  
• Covidien declares quarterly cash dividend and announces share repurchase program  Covidien announced that its Board of Directors has declared a quarterly cash dividend of $0.18 per ordinary share. The dividend is payable on May 14, 2010, to shareholders of record on April 15, 2010. Covidien also announced a program to purchase up to $1 billion of the Company's ordinary shares.
  Covidien plc March 16, 2010  
• Boston Scientific completes enrollment in PLATINUM trials  Boston Scientific announced completion of patient enrollment in the Small Vessel and Long Lesion trials of its PLATINUM clinical program that are designed to compare the platinum chromium PROMUS® Element Everolimus-Eluting Stent System to matched historical control groups of patients.
  Boston Scientific Corporation March 16, 2010  
• New PLATO sub-analysis of CABG patients presented at ACC  AstraZeneca announced results of a new analysis of the PLATO study which showed there were fewer deaths in patients with acute coronary syndromes who took the investigational oral antiplatelet BRILINTA within seven days prior to having heart bypass surgery compared to those who took clopidogrel.
  AstraZeneca March 16, 2010  
• ARIAD reports development progress and fourth quarter and year-end 2009 financial results  ARIAD Pharmaceuticals reported a net loss of $80.0 million for the full year ended December 31, 2009 versus a net loss of $71.1 million for the same period in 2008, and cash used in operations was $51.9 million, compared to cash used in operations of $48.3 million for the same period in 2008.
  ARIAD Pharmaceuticals, Inc. March 16, 2010  
• Additional $162 million in Recovery Act investment to advance health IT  U.S. Department of Health and Human Services Secretary Kathleen Sebelius announced awards to help states facilitate health information exchange and advance health information technology (health IT).
  Dept. of Health & Human Services March 15, 2010  
• Lilly to acquire global license to AXIRON testosterone solution from Acrux  Eli Lilly and Company and Acrux announced that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON(TM)).
  Eli Lilly and Company March 15, 2010  

   (next 10 articles)